Presentation7 Feb 2020 06:36
Had a read all sounding promising imo albeit to a novice.
Especially liked this.
Faron’s pipeline includes Traumakine, in development for the treatment of Acute Respiratory Distress Syndrome (ARDS), a disease with 300,000 cases annually in EU & US, 3 million worldwide and a mortality rate of 30–40%
• Factors that led to Phase III failure in 2018 are now well understood and corrected, partnering the program will provide upside